Futura Medical

What Futura Medical does

Futura Medical plc is a UK-based pharmaceutical company specializing in the development and global commercialization of consumer-focused sexual health products. Its lead commercial product is Eroxon, a fast-acting topical gel treatment for erectile dysfunction that uses a proprietary evaporative mode of action — volatile components creating a cooling and warming sensation that stimulates nerve sensors in the glans penis to induce smooth muscle relaxation and erection. Eroxon is the only FDA-authorized and CE-marked topical gel for ED available over-the-counter in both the United States and Europe, and is currently sold across 27 countries through distribution and licensing partnerships including Market Performance Group (US), Cooper Health (Europe), and Menarini (South Korea), with retail presence in pharmacy chains such as Boots in the UK and leading US retailers. The company has two pipeline assets: Eroxon Intense, a line extension seeking stronger sensorial effect (regulatory clearance expected mid-to-late 2026), and WSD4000, a development portfolio targeting female sexual dysfunction with reported 84% improvement rates in home-use studies and a planned Phase 3 trial before year-end 2026.

Futura operates a hybrid R&D and commercial model, deriving revenue from product sales and licensing/royalty streams with regional commercial partners who control local pricing and marketing, while Futura retains manufacturing responsibility and, in the US market, advertising spend control following the 2026 transition from Haleon to Market Performance Group. The company achieved its maiden profit in 2024 but FY2025 revenue has been guided to only £1.3-1.4m, well below prior expectations, and management has warned that cash runway extends only to June 2026 absent additional capital. Material risks include the May 2026 revocation (under appeal) of European Patent EP 3934624B1 covering Eroxon, the costly transition of US distribution, and ongoing shareholder dilution as evidenced by director share subscriptions at 1 pence per share in December 2025.

The company also maintains a separate India-focused medical devices platform (Futura Medtech) built with $25m of investment from Jashvik Capital, comprising acquisitions of Dolphin Sutures, Suture Planet, and Rivarp Medical — a strategic adjacency to its core sexual health business that targets India and 85+ international markets across orthopaedics, neurosurgery, sutures, and interventional cardiology. The company is publicly listed on the AIM market of the London Stock Exchange under ticker FUM, headquartered in Guildford, Surrey, and operates as a holding company over wholly-owned subsidiaries Futura Medical Developments Limited and Futura Consumer Healthcare Limited.

Name

Futura Medical

Legal name

Futura Medical plc

Website

https://futuramedical.com

Company type

Public

Founded year

1997

Operating status

Operating

Headcount range

11–50 employees

Short description

Futura Medical plc is a UK-based pharmaceutical company developing and commercializing over-the-counter topical sexual health products, principally Eroxon, a clinically proven ED gel available without prescription in 27 countries across the US, Europe, the Middle East, and Asia.

Ownership category

akta.pro rank

Product category

Sexual Health Pharmaceuticals

NAICS

Toilet Preparation Manufacturing (32562), Health and Personal Care Retailers (456)

SIC

Pharmaceutical Preparations (2834), Retail-Drug Stores And Proprietary Stores (5912)

akta.pro primary industry

Feminine & Sexual Wellness OTC (Yeast Infection OTC, Lubricants, Condoms, Pregnancy Tests) (CRADAMAH)

akta.pro secondary industry

Sexual Wellness & Intimacy Products DTC (CRAFACAM)

Keywords

• Topical ED treatment
• Sexual health products
• Erectile dysfunction gel
• OTC medical devices
• Specialty pharmaceuticals

Headquarters

HQ city

Guildford

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Product Sales: Direct product sales through retail partners and online channels for Eroxon in markets where commercial partnerships are not in place.
2. Licensing and Distribution Partnerships: Revenue from licensing deals and distribution partnerships with commercial partners like Market Performance Group (US commission-based), Cooper Health (Europe), and other regional distributors across 27 markets.
3. Futura Medtech Platform Investments: Jashvik Capital invested $25 million in Futura in 2024 to build devices and consumables across multiple specialty areas through investments in Dolphin Sutures, Suture Planet, and Rivarp Medical.

Pricing tiers

Go-to-market motion3 records

Distribution channels7 records

Marketing channels4 records

Core offering

Futura Medical develops, manufactures and globally commercialises clinically proven topical gel medical devices for sexual health, sold over-the-counter. Its lead product Eroxon® is a fast-acting, FDA- and CE-marked topical gel treatment for erectile dysfunction applied directly to the glans penis, available OTC in 27 markets across Europe, North America, and the Middle East. Revenue is generated via licensing/commission arrangements with consumer healthcare distributors (e.g., Market Performance Group in the US, Cooper Health in Europe) plus direct retail and e-commerce sales through pharmacy chains such as Boots UK.

Product overview

Futura Medical is a pharmaceutical company specializing in the development and global commercialisation of innovative consumer-focused sexual health products. The portfolio comprises three key offerings: Eroxon® (lead product), a clinically proven topical gel treatment for erectile dysfunction available over-the-counter in 27 markets; Eroxon® Intense, a line extension providing stronger sensorial action; and WSD4000, an in-development portfolio for female sexual health. The company operates a hybrid R&D and commercial strategy, partnering with distributors like Market Performance Group (US) and licensing to consumer healthcare companies across major markets.

Differentiator

Problem solved

Functional benefit

Brands

• Eroxon®: Clinically proven breakthrough topical treatment for erectile dysfunction. Fast-acting gel applied to the glans penis, available over-the-counter in Europe and USA. Works through unique evaporative mode of action creating cooling and warming action to stimulate nerve sensors.
• Eroxon® Intense
• WSD4000

Products and services

• Eroxon® A clinically proven, fast-acting topical gel treatment for erectile dysfunction (ED) applied directly to the glans penis. It works through a unique evaporative mode of action creating cooling and warming sensations that stimulate nerve sensors, leading to smooth muscle relaxation and erection. Available over-the-counter in 27 markets (Europe, USA, Mexico, Middle East), it is the only regulatory-approved topical gel treatment for ED without a doctor's prescription.
• Eroxon® Intense A line extension of Eroxon® providing stronger and faster sensorial action for men who prefer enhanced sensation. Pursued via a Special 510K submission with the US FDA. Expected regulatory clearance in EU/UK by June 2026 and US Q3 2026.
• WSD4000 An in-development portfolio of topical gels designed to treat symptoms of impaired sexual response or function (sexual dysfunction) in women, addressing gaps in women's sexual health market with improvements in sexual desire, arousal, lubrication, pain during intercourse, orgasm, and overall satisfaction. Positioned as a first-in-class De Novo medical device with OTC classification.

Quantifiable outcome

• 70-71% satisfaction rate for erection hardness in home use studies
• +3 more outcomes

Named customers2 records

Segments3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered core and regional.

• Market Performance Group (MPG)coreChannel Partner/ Reseller/ Distributor · 29 June 2026New US commercial partnership for Eroxon, effective September 1, 2026. MPG takes commercial control on commission basis while Futura retains manufacturing responsibility and advertising spend control. Futura received $1.9m early termination fee from previous partner Haleon and waived US patent milestone payment rights. The switch follows slower-than-expected US sales since Eroxon's October 2024 launch.
• Dolphin SuturesregionalStrategic or Co-development Partner · 28 April 2026First investment under Futura Medtech platform (October 2024). Manufacturer of medical devices in India market.
• Rivarp MedicalregionalStrategic or Co-development Partner · 28 April 2026Third investment under Futura Medtech platform (April 2026). Bengaluru-based manufacturer of medical devices and implants spanning orthopaedics, neurosurgery, and interventional cardiology. Founded in 2016, holds EU MDR and US FDA certifications, distributes products across India and international markets through 100+ channel partners. Investment aims to accelerate growth and portfolio innovation combining Rivarp's manufacturing capabilities with Futura's distribution network.
• Suture PlanetregionalStrategic or Co-development Partner · 1 July 2025Second investment under Futura Medtech platform (July 2025). Medical devices business in India market.
• Haleon plccoreChannel Partner/ Reseller/ Distributor · 1 July 2023Original US commercial partnership to commercialize Eroxon in the United States, with Haleon handling marketing and regulatory approvals while Futura provided technical support. Partnership terminated in 2026 due to disappointing sales performance. Futura received $1.9m early termination fee and waived US patent milestone payment rights.
• MenariniregionalChannel Partner/ Reseller/ Distributor · 23 March 2022Commercialization partner for South Korea. Menarini to commercialize MED3000 in South Korea market.
• Cooper HealthcoreChannel Partner/ Reseller/ DistributorEuropean commercial partnership for MED3000/Eroxon distribution. Major deal for Europe announced in May 2022.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Pfizer (Viagra): Global originator of Viagra (sildenafil), the dominant oral PDE5 inhibitor for erectile dysfunction. Comparable as the established category leader that Eroxon is positioning against as the first OTC topical alternative, but operates at vastly greater scale and uses an oral mechanism.
• Eli Lilly (Cialis): Originator of Cialis (tadalafil), the leading daily-use oral ED medication. Comparable as a broad incumbent in the ED therapeutics market against which Eroxon competes on OTC convenience and topical mechanism.
• Church & Dwight: Consumer packaged goods company with sexual wellness portfolio (Trojan condoms, personal lubricants). Comparable as an OTC sexual wellness brand owner distributing through major retailers, with a much broader portfolio including contraceptives.
• Ansell: Global sexual wellness brand owner (Lifestyle condoms, SKYN). Comparable as an OTC sexual wellness manufacturer with established global distribution and brand equity in adjacent categories.
• Mylan / Viatris (generic sildenafil): Major generic pharmaceutical manufacturer producing low-cost sildenafil citrate. Comparable as the primary low-cost generic PDE5 alternative whose price competition structurally constrains OTC premium pricing for Eroxon.

Direct peers

• Hims & Hers Health: Direct-to-consumer telehealth platform selling prescription ED treatments (sildenafil, tadalafil) online. Comparable as a DTC-focused sexual wellness brand targeting the same consumer segment Eroxon targets, but with oral prescription medications.
• Ro (Roman): DTC men's health platform offering prescription ED treatments via telehealth and online pharmacy. Comparable as a direct-to-consumer sexual wellness brand competing for the same mild-to-moderate ED patient seeking convenient, stigma-free treatment.
• Promescent: Topical desensitizing spray for premature ejaculation sold OTC. Comparable as an OTC topical male sexual health product targeting men seeking non-prescription alternatives to oral medications.

Emerging players

• Vella Bioscience: Women's sexual wellness company developing topical treatments for female sexual dysfunction and libido. Comparable as an emerging player targeting the same WSD4000 opportunity in female sexual health with a focus on non-prescription solutions.
• Mosaic Wellness (Man Matters): India-based DTC men's wellness platform offering sexual health products including ED treatments. Comparable as an emerging DTC sexual wellness brand operating in similar channels and targeting similar consumer demographics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/bluediamondnl
• Facebookfacebook.com/bluediamondnl
• LinkedInlinkedin.com/company/futura-medical

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Futura Medical